Abbott Laboratories [ABT] Stock trading around $108.30 per share: What’s Next?


Abbott Laboratories [NYSE: ABT] price plunged by -0.54 percent to reach at -$0.59. The company report on July 12, 2022 that Abbott Receives FDA’s Breakthrough Device Designation to Explore Use of Deep Brain Stimulation to Manage Severe Depression.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Breakthrough Device Designations are given by the U.S. FDA to expedite the review of technologies that can improve the lives of people with life-threatening or debilitating conditions.

Each year, 2.8 million Americans will fail multiple depression therapies and be diagnosed with treatment-resistant depression (TRD).

A sum of 5750160 shares traded at recent session while its average daily volume was at 5.39M shares. Abbott Laboratories shares reached a high of $110.37 and dropped to a low of $107.697 until finishing in the latest session at $108.30.

The one-year ABT stock forecast points to a potential upside of 20.34. The average equity rating for ABT stock is currently 2.00, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Abbott Laboratories [ABT]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABT shares is $135.96 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABT stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Wolfe Research have made an estimate for Abbott Laboratories shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on July 06, 2022. While these analysts kept the previous recommendation, BofA Securities raised their target price to Buy. The new note on the price target was released on March 02, 2022, representing the official price target for Abbott Laboratories stock. Previously, the target price had yet another raise from $138 to $142, while UBS kept a Buy rating on ABT stock. On January 27, 2022, analysts decreased their price target for ABT shares from 150 to 143.

The Average True Range (ATR) for Abbott Laboratories is set at 2.48, with the Price to Sales ratio for ABT stock in the period of the last 12 months amounting to 4.27. The Price to Book ratio for the last quarter was 5.39, with the Price to Cash per share for the same quarter was set at 4.65. Price to Free Cash Flow for ABT in the course of the last twelve months was 38.64 with Quick ratio for the last quarter at 1.40.

ABT Stock Performance Analysis:

Abbott Laboratories [ABT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.91. With this latest performance, ABT shares dropped by -3.91% in over the last four-week period, additionally sinking by -20.11% over the last 6 months – not to mention a drop of -8.85% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABT stock in for the last two-week period is set at 46.80, with the RSI for the last a single of trading hit 47.24, and the three-weeks RSI is set at 46.24 for Abbott Laboratories [ABT]. The present Moving Average for the last 50 days of trading for this stock 110.65, while it was recorded at 108.93 for the last single week of trading, and 121.42 for the last 200 days.

Insight into Abbott Laboratories Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Abbott Laboratories [ABT] shares currently have an operating margin of +21.36 and a Gross Margin at +53.89. Abbott Laboratories’s Net Margin is presently recorded at +16.35.

Return on Equity for this stock inclined to 20.53, with Return on Assets sitting at 9.53.

Abbott Laboratories’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.90.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Abbott Laboratories go to 12.60%.

Abbott Laboratories [ABT] Insider Position Details

There are presently around $140,285 million, or 75.50% of ABT stock, in the hands of institutional investors. The top three institutional holders of ABT stocks are: VANGUARD GROUP INC with ownership of 151,288,441, which is approximately 1.432% of the company’s market cap and around 0.50% of the total institutional ownership; BLACKROCK INC., holding 132,854,732 shares of the stock with an approximate value of $14.47 billion in ABT stocks shares; and CAPITAL RESEARCH GLOBAL INVESTORS, currently with $8.78 billion in ABT stock with ownership of nearly -4.098% of the company’s market capitalization.

Positions in Abbott Laboratories stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 1,238 institutional holders increased their position in Abbott Laboratories [NYSE:ABT] by around 50,022,290 shares. Additionally, 1,231 investors decreased positions by around 62,211,765 shares, while 426 investors held positions by with 1,176,087,826 shares. The mentioned changes placed institutional holdings at 1,288,321,881 shares, according to the latest SEC report filing. ABT stock had 137 new institutional investments in for a total of 5,121,031 shares, while 164 institutional investors sold positions of 7,287,846 shares during the same period.